EU-129

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameEU-129

Drug Alias NameEngineered ACE-2-IgG1-Fc Fusion Protein Targeting SARS-CoV-2 Receptor-Binding Domain Protein (Eutilex/Chonbuk National University)engineered ACE-2-IgG1-Fc fusion protein targeting SARS-CoV-2 receptor-binding domain protein (Eutilex/Chonbuk National University)EU-129

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionCoronavirus spike glycoprotein inhibitorsAngiotensin-converting enzyme 2 inhibitors

TargetsAngiotensin-converting enzyme 2Coronavirus spike glycoprotein

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesChonbuk National University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesChonbuk National University Eutilex

Active IndicationsN/A

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Neoplasms

Other Information

ATC CodeN/A